Movement Disorders Clinical Practice, published by WILEY, is an essential peer-reviewed journal dedicated to advancing the understanding and treatment of movement disorders from a clinical perspective. With an ISSN of 2330-1619, this journal serves as a vital resource for researchers, clinicians, and students engaged in neurology and clinical neuroscience. Since its inception in 2014, the journal has established itself within the medical community, currently positioned in the Q2 category for both Neurology and Neurology (Clinical), reflecting its influence and reputation. Although it does not offer open access, the journal is integral for disseminating high-quality research and clinical insights, thereby contributing significantly to improved patient care and outcomes in the field of movement disorders. Based in Hoboken, NJ, it continues to attract contributions from leading experts and aims to foster a deeper understanding and dialogue surrounding contemporary challenges and advancements in movement disorder treatment.

Kidney Diseases is an esteemed open-access journal published by KARGER that has been at the forefront of nephrology research since its inception in 2015. With an impressive Scopus ranking of #13 out of 81 in the field of Medicine Nephrology, placing it in the top 84th percentile, the journal has established itself as a vital resource for researchers, clinicians, and students interested in advancing knowledge on kidney health, disorders, and innovative treatment strategies. This journal aims to disseminate cutting-edge findings and clinical insights over a converged publication span from 2019 to 2024, fostering global collaboration and dialogue within the scientific community. With its commitment to open access, Kidney Diseases ensures that critical research is freely accessible, promoting wider dissemination of knowledge and the development of effective therapeutic interventions.

Blood Advances is a premier, peer-reviewed journal published by Elsevier, dedicated to the field of hematology. With an impressive impact factor and classified within the Q1 category of hematology for 2023, it ranks as the 16th out of 137 journals in the Scopus Medicine Hematology category, placing it in the top 88th percentile globally. This influential journal, which has been disseminating invaluable research since its inception in 2017, focuses on advancing knowledge and innovation in blood science, including clinical and laboratory aspects of hematology. Although it offers limited open access features, its comprehensive scope encompasses various topics relevant to both researchers and practitioners. Located in the United States and managed from Amsterdam, Blood Advances provides a vital platform for the dissemination of groundbreaking research, making significant contributions to the understanding and treatment of blood disorders. Researchers, professionals, and students alike will find this journal an essential resource for keeping abreast of the latest developments and advancements in hematology.

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

AMERICAN JOURNAL OF GASTROENTEROLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal in the field of gastroenterology and hepatology, boasting a notable impact factor that underscores its influence in the medical community. With an ISSN of 0002-9270 and an E-ISSN of 1572-0241, this journal has a long-standing tradition since its inception in 1938, officially recognized from the year 1947 to 2024. It holds esteemed positions in Q1 quartiles for both gastroenterology and hepatology as of 2023, reflecting its high-quality research output and its crucial role in advancing medical knowledge. Ranked 13th out of 167 in the field of Gastroenterology and 13th out of 82 in Hepatology by Scopus, it serves as an essential resource for researchers, professionals, and students alike, fostering an environment for the dissemination of groundbreaking studies and insights in gastrointestinal health. Its comprehensive focus on clinical and translational aspects aims to illuminate the complexities of digestive diseases, promising to contribute significantly to advancements in patient care and treatment methodologies.

Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.

Welcome to the Indian Journal of Rheumatology, a premier scholarly platform dedicated to advancing research and clinical practice in the field of rheumatology. Published by SAGE Publications Inc., this journal has been providing open access to its valuable content since 2006, promoting the dissemination of knowledge in India and beyond. As a voice in the rheumatology community, the journal addresses a wide range of topics including epidemiology, diagnostics, treatment strategies, and patient care in rheumatic diseases. Despite being classified in the Q4 category of the 2023 Scopus rankings, with a current position of Rank #57 among 73 journals, it serves as an essential resource for researchers, healthcare professionals, and students seeking to stay updated with the latest developments. The journal is committed to fostering scholarly dialogue and facilitating access to research that influences practice and improves patient outcomes in rheumatologic care.

Current Oncology is a prominent open-access journal dedicated to the field of oncology, published by MDPI in Switzerland. With an ISSN of 1198-0052 and E-ISSN 1718-7729, this esteemed journal has been providing valuable insights since its inception in 1998 and continues to publish cutting-edge research through 2024. Recognized for its contribution to the medical community, Current Oncology holds a 2023 Q2 category rank in Oncology and is positioned at the 41st percentile among its peers in Scopus rankings. As a hub for innovation and discussion in cancer research, it offers a plethora of articles that span various aspects of oncology, making it an essential resource for researchers, professionals, and students alike. Since becoming fully open-access in 2006, it provides expanded accessibility to groundbreaking studies and findings, fostering collaboration and knowledge exchange across the global research community. With its central location in Basel, Switzerland, Current Oncology plays a pivotal role in advancing oncology's frontiers.

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.